1248541-63-0

Basic information

• Product Name: 2,3-DiaMino-5-broMobenzoic acid Methyl ester
• Synonyms: 2,3-DiaMino-5-broMobenzoic acid Methyl ester;Methyl-2,3-diaMino-5-broMobenzoate;Benzoic acid, 2,3-diamino-5-bromo-, methyl ester;Methyl 5-bromo-2,3-diaminobenzoate
• CAS NO: 1248541-63-0
• Molecular Formula: C₈H₉BrN₂O₂
• Molecular Weight: 245.07326
• Mol File: 1248541-63-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 351.9±37.0 °C(Predicted)
• Appearance: /
• Density: 1.655±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.94±0.10(Predicted)
• CAS DataBase Reference: 2,3-DiaMino-5-broMobenzoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DiaMino-5-broMobenzoic acid Methyl ester(1248541-63-0)
• EPA Substance Registry System: 2,3-DiaMino-5-broMobenzoic acid Methyl ester(1248541-63-0)

Safety Data

• Hazardous Substances Data: 1248541-63-0(Hazardous Substances Data)

Usage

Uses

Methyl 2,3-diamino-5-bromobenzoate

Upstream product

• 636581-61-8 2-amino-5-bromo-3-nitrobenzoic acid methyl ester 
• 58580-07-7 2-amino-5-bromo-3-nitro-benzoic acid 
• 57113-91-4 methyl 3-nitroanthranilate 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 49764-59-2 5-bromo-7-nitro-1H-indole-2,3-dione 

Downstream Products

• 861259-02-1 6-bromo-2-(2,3-dichloro-phenylamino)-3H-benzoimidazole-4-carboxylic acid methyl ester 

Relevant articles and documents

1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS

The present invention provides 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitor compounds of formula (I), which may be therapeutically useful as DHODH inhibitors, in which R1 to R3

SUBSTITUTED QUINOXALINE DERIVATIVES

The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.